FINWIRES · TerminalLIVE
FINWIRES

SHA:601607

11 stories mentioning SHA:601607Updated just now

Every FINWIRES story that references SHA:601607, newest first.

Asia

Shanghai Pharmaceuticals Unit Gets Canada Product Licenses for Three Products

Shanghai Pharmaceuticals (SHA:601607) subsidiary Shanghai Zhonghua has obtained Canadian product licenses from Health Canada's Natural and Non-prescription Health Products Directorate for three Longhu-branded products.The products-Cooling Balm Classic, Cooling Balm Ultra and Roll-on Essential Balm-are mainly used for relieving muscle and joint aches, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.

SHA:601607
Asia

Shanghai Pharmaceuticals Subsidiary Gets China Drug Registration Certificate for High Cholesterol Tablets

Shanghai Pharmaceuticals (SHA:601607) subsidiary Changzhou Pharmaceutical Factory received a drug registration certificate from China's National Medical Products Administration for its rosuvastatin ezetimibe tablets, according to a Friday filing with the Shanghai Stock Exchange.The drug is indicated for high cholesterol or homozygous familial hypercholesterolemia, the company said.Mainland Chinese hospitals have so far purchased 25.7 million yuan worth of the drug in 2025.

SHA:601607
Asia

Shanghai Pharmaceuticals Ends Clinical Trial on Salvianolic Acid A for Injection

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) decided to terminate the clinical trial and development of salvianolic acid A for injection, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's Hong Kong shares rose 2% during Monday's afternoon trade.The drug was intended for the treatment of angina pectoris associated with coronary heart disease.The company said the decision was made to optimize the allocation of funds on projects with "greater strategic advantages".

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Unit Gets China Clinical Trial Approval for Dry Eye Drug

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received clinical trial approval from China's National Medical Products Administration for its Qingrun Yangmu traditional Chinese drug, according to a Tuesday filing with the Shanghai bourse.Qingrun Yangmu, developed by subsidiary Shanghai Pharmaceuticals Group Institute of Traditional Chinese Medicine, is indicated for dry eye.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Arm to Divest 41% Stake in Subsidiary Through Public Listing

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) subsidiary Shanghai Pharmaceutical Holdings will sell a 41% stake in subsidiary Shanghai Pharmaceutical Yiyao Pharmaceutical (Shanghai) for 329.8 million yuan via a public listing, according to a Saturday filing with the Shanghai bourse.Following the transaction, Shanghai Pharma Holdings' ownership in the unit will drop from 51% to 10% and Shanghai Pharmaceutical Holdings will no longer be part of its financial statements.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Commits 300 Million Yuan in Biomedicine Fund

Shanghai Pharmaceuticals (SHA:601607) committed 300 million yuan to participate in a 2-billion-yuan private equity fund focused on early-stage biomedical innovation.The Shanghai Shangshi Biomedicine Industry Private Fund primarily focuses on assets from investigational new drugs to second-phase clinical trials, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.

SHA:601607
Asia

Shanghai Pharmaceuticals Subsidiary Gets Supplementary Drug Approval for Anti-Organ Rejection Tablets

China's drug regulator granted Shanghai Pharmaceuticals (SHA:601607) subsidiary Shanghai Shangyao Xinyi Pharmaceutical Factory a supplementary approval for azathioprine tablets, according to a Tuesday disclosure to the Shanghai bourse.Azathioprine is used with corticosteroids and other immunosuppressants to prevent organ rejection for transplant patients, according to the filing.

SHA:601607
Asia

Shanghai Pharmaceuticals Gets China Approval for Spasm Drug for Infants

China's drug regulator approved Shanghai Pharmaceuticals' (SHA:601607) vigabatrin oral solution powder, according to a Tuesday filing with the Shanghai bourse.The drug is indicated for spasms in infants and children ranging from 1 month to 2 years of age.

SHA:601607
Asia

Shanghai Pharmaceuticals Gets Nod for Manufacturing of Roxadustat Capsules

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received a drug registration certificate from China's National Medical Products Administration for the manufacturing of Roxadustat capsules, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's Hong Kong shares rose 1% during Monday's afternoon trade.The drug is used for the treatment of anemia caused by chronic kidney disease.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Gains Thai Approval for Rivaroxaban Tablets

Shanghai Pharmaceuticals (SHA:601607) unit Changzhou Pharma obtained Thai Food and Drug Administration approval for rivaroxaban tablets in 10-milligram, 15-milligram and 20-milligram strengths.The generic drug is used to reduce stroke risk in non-valvular atrial fibrillation patients and treat deep vein thrombosis and pulmonary embolism, according to a Friday filing with the Shanghai bourse.

SHA:601607
Asia

Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.

HKG:2607SHA:601607

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:601607 in your portfolio
WheelAI
WheelAI
Analyze SHA:601607 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:601607